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Summary
Vitamin K antagonists (VKAs) used for the prevention and treatment of
thromboembolic disease, increase the risk of bleeding complications. We
developed and validated a model to predict the risk of an international
normalised ratio (INR) ≥ 45 during a hospital stay. Adult patients admit-
ted to a tertiary hospital and treated with VKAs between 2006 and 2010
were analysed. Bleeding risk was operationalised as an INR value ≥45.
Multivariable logistic regression analysis was used to assess the association
between potential predictors and an INR ≥ 45 and validated in an inde-
pendent cohort of patients from the same hospital between 2011 and 2014.
We identified 8996 admissions of patients treated with VKAs, of which
1507 (17%) involved an INR ≥ 45. The final model included the following
predictors: gender, age, concomitant medication and several biochemical
parameters. Temporal validation showed a c statistic of 071. We developed
and validated a clinical prediction model for an INR ≥ 45 in VKA-treated
patients admitted to our hospital. The model includes factors that are col-
lected during routine care and are extractable from electronic patient
records, enabling easy use of this model to predict an increased bleeding
risk in clinical practice.
Keywords: prediction model, bleeding risk, vitamin K antagonists,
INR ≥ 45, hospitalization.
Vitamin K antagonists (VKAs) are frequently used medica-
tions in the prevention and treatment of thromboembolic
disease (Wysowski et al, 2007; Ansell et al, 2008). However,
the benefit of their use is partially offset by the increased risk
of bleeding complications. The reported overall risk of major
bleeding complications is 14–21 per 100-person years of
VKA treatment (Palareti et al, 1996; Schulman et al, 2008;
Roskell et al, 2012).
The risk of bleeding is related to the international nor-
malised ratio (INR) and is influenced by many factors, such
as dietary intake of vitamin K, concomitant medication,
comorbidities and genetic factors (Schulman et al, 2008).
Although numerous risk factors have been linked to a higher
bleeding risk, it is difficult for physicians to assess the risk of
bleeding by VKAs for an individual patient. Prediction mod-
els could help physicians to predict VKA-associated bleeding
complications and make more accurate assessments, which
may lead to adjustments in therapy or closer monitoring.
Prediction models for bleeding complications or a
supratherapeutic INR in patients on VKA therapy can be
found in the literature (Beyth et al, 1998; Kuijer et al, 1999;
Gage et al, 2006; Shireman et al, 2006; Ruiz-Gimenez et al,
2008; Pisters et al, 2010; Fang et al, 2011; Hippisley-Cox &
Coupland, 2014; Focks et al, 2016). Given that bleeding itself
is often not registered electronically, supratherapeutic INR
can be used as a substitute as this is a proven risk factor for
bleeding complications (Palareti et al, 1996; Hylek et al,
2003; Amouyel et al, 2009). Generally, these prediction mod-
els include comorbidities, such as hypertension (Gage et al,
2006; Pisters et al, 2010; Fang et al, 2011; Hippisley-Cox &
Coupland, 2014), history of stroke (Beyth et al, 1998; Gage
et al, 2006; Pisters et al, 2010), prior bleeding (Beyth et al,
1998; Gage et al, 2006; Shireman et al, 2006; Pisters et al,
2010; Fang et al, 2011), malignancy (Kuijer et al, 1999; Gage
et al, 2006; Ruiz-Gimenez et al, 2008), genetic polymorphism
(Gage et al, 2006) or fall risk (Gage et al, 2006). These are
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mainly risk factors that are not easily extractable from elec-
tronic medical records (EMRs). Therefore, the available pre-
diction models cannot be implemented as electronic clinical
decision support rules (‘clinical rules’). Yet, the application
of such rules would greatly assist physicians to identify those
patients for whom the risk of bleeding is high.
Furthermore, most models focus on patients with a speci-
fic indication, such as atrial fibrillation (AF) (Gage et al,
2006; Shireman et al, 2006; Pisters et al, 2010; Fang et al,
2011; Focks et al, 2016) or venous thromboembolism (VTE)
(Kuijer et al, 1999; Ruiz-Gimenez et al, 2008), and are
derived from cohorts of patients in ambulatory care (Beyth
et al, 1998; Ruiz-Gimenez et al, 2008; Fang et al, 2011), or
ambulatory and hospitalised patients together (Kuijer et al,
1999; Gage et al, 2006; Pisters et al, 2010).
Factors associated with the occurrence of bleeding in non-
selected patient populations during a hospital stay might be
different from those during ambulatory care. Existing predic-
tion models for bleeding events in patients using VKAs are
not applicable for clinical rules and do not concern the gen-
eral hospitalised population.
Therefore, we aimed to develop a model predicting the
risk of an INR ≥ 45 during hospital stay, for adult patients
who are treated with VKAs, based on risk factors that are
electronically collected during routine care.
Methods
Study design
This study was designed as a cohort study. Data were
prospectively recorded and retrospectively analysed. The
medical ethics committee granted permission for this study.
Study setting
The study was conducted in the Erasmus University Medical
Centre (Erasmus MC), a 1320-bed University Medical Centre
based in Rotterdam, the Netherlands.
Study population
Patients aged 18 years and older who were admitted to the
Erasmus MC between January 2006 and December 2010 and
treated with VKAs were included in the study. The VKAs
used were acenocoumarol (B01AA07) and phenprocoumon
(B01AA04), and are the most commonly used VKAs in the
Netherlands. Exclusion criteria were the following: (i)
patients with an admission to the intensive care unit (ICU),
(ii) patients without an INR measurement during their treat-
ment with a VKA, (iii) patients with an INR ≥ 45 as reason
for hospitalization, which is defined as the occurrence of an
INR ≥ 45 within 12 h after hospitalization.
Patients were considered at risk in the period between
start of the prescription of the VKA until the end of the
hospital prescription, plus a wash-out period. The wash-out
period of a maximum of 5 times the elimination half-life was
set to 5 days for acenocoumarol and 14 days for phenpro-
coumon (Palareti et al, 1996).
Data collection
The hospital information system was used for data collection
(Table SI). Patient data were coded according to Dutch pri-
vacy guidelines. Bleeding risk was operationalised as
INR ≥ 45. Data were collected from start of VKA treatment
until the first occurrence of an INR ≥ 45 or until the end of
exposure to VKAs, discharge, in-hospital death, or until the
end of the study (31 December 2010 for the development
cohort and 31 December 2014 for the validation cohort),
whichever came first.
Candidate predictors
The following candidate predictors were included in the analy-
sis: gender, age, occurrence of an INR ≥ 45 during a previous
admission (yes/no), type of VKA (acenocoumarol/phenpro-
coumon), concomitant use of known interacting drugs and
type of ward (medical/surgical). The cardiology wards, internal
medicine wards, oncology wards and psychiatry wards were
classified as ‘medical’, and the surgical wards, ear-nose-throat
and eye surgery wards were classified as ‘surgical’. We also
considered the most recently (with a maximum of 7 days)
measured laboratory value in the week before start of VKA
therapy of alanine aminotransferase (ALAT), aspartate amino-
transferase (ASAT), gamma-glutamyl transferase (GGT), lac-
tate dehydrogenase (LDH), albumin, estimated glomerular
filtration rate (e-GFR) calculated with the modification of diet
in renal disease (MDRD) formula (Levey et al, 1999), haemo-
globin (Hb), creatinine, thyroid stimulation hormone (TSH),
triiodothyronine (T3), thyroxin (T4), C-reactive protein
(CRP), platelet count (Plt) and leucocyte count (Leu).
We defined concomitant use of known interacting drugs
as an active prescription at the same time the VKA was pre-
scribed, or when the interacting drug was stopped before
start of VKA but within the wash-out period of a maximum
of 5 times the elimination half-life of the interacting drug
(Palareti et al, 1996). The following drugs were considered as
interacting drugs that increase the effect of VKAs the most;
miconazole, cotrimoxazole, fluconazole, voriconazole and
amiodarone. Rifampicin, carbamazepine, phenytoin,
colestyramin and anti-thyroid drugs were considered to
decrease the effect of VKAs the most (De Federatie van
Nederlandse Trombosediensten).
Statistical analysis
All data were analysed using R (The R Foundation for Statis-
tical Computing, Vienna, Austria). Missing values of candi-
date predictors were filled in with multiple imputation (MI).
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Each missing value was imputed ten times. Imputed values
were drawn from the predictive distribution in an imputation
model that included all candidate predictors and the outcome
(INR ≥ 45). MI resulted in ten complete datasets, which were
analysed with standard data methods. The results were com-
bined to produce overall estimates and standard errors that
reflect missing data uncertainty (Van Buuren et al, 2006). Uni-
variable and multivariable logistic regression analysis was used
to assess the association of candidate predictors with the risk
of an INR ≥ 45. As some patients were included multiple
times for the recreation of our model we used random effect
modelling (Harrell, 2001). For the continuous predictor age, a
linear relationship with outcome was found to be a good
approximation after assessment of nonlinearity using
restricted cubic splines (Harrell, 2001). Age was included as
piecewise linear with two pieces, up to 60 years and above
60 years, for a better description of the shape of the associa-
tion with an INR ≥ 45. Some laboratory values (LDH and
CRP) were log transformed for the same reason. Odds ratios
for continuous variables were given for the 75th percentile ver-
sus 25th percentile of the variable. Using a backward elimina-
tion strategy with P < 015, the strongest prognostic factors
were included in the final model (Steyerberg, 2008).
Internal validation
Despite the large cohort (N = 8996), the number of events
were limited (N = 1507). Therefore we used bootstrap
resampling to adjust for possible over-fitting and optimistic
performance of the model. One hundred bootstrap samples
were drawn with replacement; a prognostic model was devel-
oped in each sample; and the performance was evaluated in
the bootstrap sample and in the original sample. The average
calibration slope of the bootstrap procedure was used to
shrink the regression coefficients in the final model. The
resulting final model was applied in an Excel risk calculator.
The discriminative ability of the model was assessed with the
concordance statistic (c-statistic). Calibration was assessed
with the calibration intercept and slope.
External validation
In order to validate the clinical prediction model, it was
applied to a separate cohort of patients who were treated
with VKAs and admitted to medical or surgical wards
between 2011 and 2014 in the Erasmus MC. These patients
were enrolled according to the same criteria as the patients
in the development cohort.
Results
Cohort description
The study included 8996 admissions of 6073 individual
patients treated with VKAs (Table I). The median length of
stay per admission was 6 days (interquartile range 3–11).
The median age was 72 (interquartile range 62–82) years and
41% of patients were female. Acenocoumarol was prescribed
more often (in 89% of admissions) than phenprocoumon (in
11% of admissions). We identified 1507 admissions (17%)
with an INR ≥ 45 for 1112 individual patients.
Table I. Baseline characteristics of the patients included in the devel-
opment and validation cohorts, number of patients (%) unless other-
wise stated.
Characteristic
Development
cohort
(2006–2010)
(n = 8996)
Validation
cohort
(2011–2014)
(n = 9018)
Male gender 5310 (590) 5420 (601)
Age, years* 72 (620–820) 690 (580–770)
INR ≥ 45 during
a previous admission
868 (96) 813 (90)
VKA type,
acenocoumarol
7978 (887) 8192 (908)
Ward type, medical ward 5497 (598) 5112 (567)
Use of concomitant
medication
Miconazole 153 (17) 82 (09)
Cotrimoxazole 337 (37) 214 (24)
Fluconazole 119 (13) 52 (06)
Voriconazole 7 (01) 27 (03)
Amiodarone 724 (80) 720 (80)
Rifampicin 53 (06) 58 (06)
Carbamazepine 73 (08) 49 (05)
Phenytoin 89 (10) 54 (06)
Colestyramin 17 (02) 89 (10)
Anti-thyroid drugs 110 (12) 75 (08)
Laboratory parameters
ALAT (u/l)* 250 (160–440) 250 (170–430)
ASAT (u/l)* 300 (220–440) 310 (230–460)
GGT (u/l)* 610 (330–1310) 660 (320–1443)
LDH (u/l)* 4425 (3570–5898) 2510 (1980–3280)
Albumin (g/l)* 360 (310–410) 370 (320–420)
e-GFR
(ml/min/173 m2)*
700 (490–900) 680 (470–890)
Hb (g/l)* 116 (100–134) 116 (102–134)
TSH (mu/l)* 14 (07–28) 17 (10–30)
T3 (nmol/l)* 14 (10–18) 15 (14–19)
T4 (nmol/l)* 1045 (835–1320) 965 (795–1235)
CRP (mg/l)* 300 (80–820) 230 (54–650)
Plt (9109/l)* 2290 (1750–3008) 2165 (1650–2880)
Leu (9109/l)* 84 (65–111) 87 (67–115)
ALAT, alanine amino transferase; ASAT, aspartate amino transferase;
CRP, C-reactive protein; e-GFR, estimated glomerular filtration rate,
calculated with the modification of diet in renal disease formula
(Levey et al, 1999); GGT, gamma-glutamyl transferase; Hb, haemo-
globin; INR, international normalised ratio; LDH, lactate dehydroge-
nase; Leu, leucocyte count; Plt, platelet count; T3, triiodothyronine;
T4, thyroxin; TSH, thyroid stimulation hormone; VKA, vitamin K
agonist.
*Results are presented as median (interquartile range).
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Prediction model
After multivariate analysis, the following variables were iden-
tified as predictors: gender, age, ALAT, albumin, e-GFR, and
the natural logarithm (Ln) of both LDH and CRP. The
strongest predictors for an INR ≥ 45 during hospitalization
were concomitant use of miconazole, cotrimoxazole, flucona-
zole, voriconazole, amiodarone or anti-thyroid drugs. The
odds ratio (OR) and 95% confidence intervals (CI) are
shown in Table II. The predicted risk of an INR ≥ 45 during
hospital stay was calculated using the formula detailed in
Table III. TSH, T3 and T4 There were too many missing val-
ues for TSH, T3 and T4 and these were excluded from the
analysis. The variables for which laboratory values were miss-
ing are listed in Table SII.
Internal validation
Bootstrapping resulted in a shrinkage factor of 095. The c-
statistic was 072 before and 071 after shrinkage, which
shows our initial model had only minor optimism.
External validation
We identified 1,227 admissions (14%) with an INR ≥ 45 for
1052 individual patients in the validation cohort. External, tem-
poral validation resulted in a c-statistic of 071, which shows
that the prediction model is applicable to patients that were hos-
pitalised in a different time period than that of our development
cohort. The calibration plots represent the agreement between
the predicted and observed INR values ≥ 45 (Fig 1). The cali-
bration-in-the-large was 034 and the calibration slope was 106.
After correction for the calibration-in-the-large, the calibration-
in-the-large was 0 and the calibration slope was 106.
Figure 2 is a score chart that is based on the formula
detailed in Table III. The score chart can be used to obtain
approximate predictions for individual patients. For example,
according to Fig 2, for an 80-year-old woman, admitted to a
medical ward with an ALAT of 23 u/l, LDH of 370 u/l, albu-
min of 40 g/l, e-GFR of 30 ml/min/173 m2, and a CRP of
80 mg/l and treated with phenprocoumon, fluconazole and
amiodarone, the risk of an INR ≥ 45 during her hospital
stay would be 108%.
Table II. Associations between predictors and bleeding complications.
Characteristic Coding
Odds ratio (95% confidence interval)
Univariable Multivariable
Gender Female versus male 129 (113–148) 119 (104–136)
Age, years >60 vs. ≤60 172 (150–197) 138 (120–159)
INR ≥ 45 during a previous admission INR ≥ 45 vs. INR < 45 139 (115–167) –
VKA type Phenprocoumon versus acenocoumarol 098 (079–121) –
Ward type Surgical ward versus medical ward 106 (093–121) –
Concomitant medication
Miconazole Miconazole versus no miconazole 270 (182–400) 185 (124–278)
Cotrimoxazole Cotrimoxazole versus no cotrimoxazole 241 (181–319) 220 (163–298)
Fluconazole Fluconazole versus no fluconazole 355 (232–544) 268 (168–429)
Voriconazole Voriconazole versus no voriconazole 1751 (255–12041) 936 (153–5746)
Amiodarone Amiodarone versus no amiodarone 223 (181–275) 228 (182–287)
Rifampicin Rifampicin versus no rifampicin 206 (101–420) –
Carbamazepine Carbamazepine versus no carbamazepine 089 (042–190) –
Phenytoin Phenytoin versus no phenytoin 166 (092–299) –
Colestyramin Colestyramin versus no colestyramin 336 (107–1060) –
Anti-thyroid drugs Anti-thyroid drugs versus no anti-thyroid drugs 209 (125–350) 180 (108–300)
Laboratory parameters
ALAT (u/l) 098 (092–105) 093 (087–098)
ASAT (u/l) 105 (099–111) –
GGT (u/l) 135 (114–159) –
LDH (u/l) 148 (129–169) 134 (120–149)
Albumin (g/l) 052 (044–061) 066 (055–078)
e-GFR (ml/min/173 m2) 069 (063–076) 068 (058–080)
Hb (g/l) 047 (040–054) –
CRP (mg/l) 246 (208–291) 162 (131–200)
Plt (9109/l) 094 (082–107) –
Leu (9109/l) 147 (132–164) –
ALAT, alanine amino transferase; ASAT, aspartate amino transferase; CRP, C-reactive protein; e-GFR, estimated glomerular filtration rate, calcu-
lated with the modification of diet in renal disease formula (Levey et al, 1999); GGT, gamma-glutamyl transferase; Hb, haemoglobin; INR, inter-
national normalised ratio; LDH, lactate dehydrogenase; Leu, leucocyte count; Plt, platelet count; VKA, vitamin K agonist.
A. R. Dreijer et al
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Discussion
We developed and validated a clinical prediction model for
the risk of an INR ≥ 45 in patients admitted to medical or
surgical wards who are treated with VKAs. The prediction
model can help physicians to identify patients at the lower
spectrum of thromboembolic risk and those for whom the
risk of bleeding during VKA therapy is high. Using the pre-
diction model may also help when counselling and informing
patients about their potential risk for haemorrhage while on
anticoagulants, and in identifying patients who might benefit
from more careful management of anticoagulation.
To our knowledge, this is the first study to develop such a
clinical prediction model.
The strongest predictors for an INR ≥ 45 during hospital-
ization were concomitant use of voriconazole, fluconazole,
amiodarone, cotrimoxazole or miconazole. These drugs inhi-
bit the metabolism of VKAs by inhibiting the liver enzyme
CYP2C9 (Harder & Thurmann, 1996; Cadiou et al, 2008),
and thus, an increased risk of an INR ≥ 45 is expected.
Concomitant use of rifampicin, carbamazepine, phenytoin or
colestyramin showed no association of the occurrence of an
INR ≥ 45. These medications induce the metabolism of
VKAs by inducing the liver enzyme CYP2C9, and thus, a
decreased risk of an INR ≥ 45 was expected. We expected to
find a similar effect of anti-thyroid drugs, which also induce
the metabolism of VKAs leading to a decrease of an
INR ≥ 45. However, our study showed an increased risk of
an INR ≥ 45 when anti-thyroid drugs were used concomi-
tantly. We have no explanation for this.
In our study we found that women had a 12-fold (95%
CI, 11–14) higher risk of an INR ≥ 45 than men. Our
results are in line with prior studies that found an increased
frequency of bleeding among women treated with VKAs.
Cosma Rochat et al (2009) found that hospitalised women
receiving vitamin K antagonists had a 4-fold increased risk of
bleeding compared with men. A possible explanation for the
higher bleeding risk in women may be a systematic sex dif-
ference in the coagulation and fibrinolytic cascades (Reynolds
et al, 2007; Cosma Rochat et al, 2009).
Furthermore, advanced age was associated with an
increased risk of an INR ≥ 45, a finding that is consistent
with previous studies (Kuijer et al, 1999; Torn et al, 2005;
Gage et al, 2006; Pisters et al, 2010). The predictors ‘type of
ward’ and ‘type of VKA’ showed no relationship with
INR ≥ 45 in this study. Gadisseur et al (2002) found that
the short acting acenocoumarol is associated with more vari-
ability in INR, but this did not lead to a higher risk of over-
anticoagulation compared to phenprocoumon in our study.
The risk profile and metabolism of warfarin, which is the
main VKA used in other countries, is generally similar to
that of acenocoumarol and phenprocoumon (Ufer, 2005;
Beinema et al, 2008). These VKAs differ in elimination half-
life and response to polymorphisms in the gene coding for
the metabolizing enzyme CYP2C9. Acenocoumarol has the
shortest half-life (08:00–14:00 h) and greatest response to
polymorphisms. Phenprocoumon has the longest elimination
half-life (12:00–20:00 h) and lowest response. The half-life of
warfarin ranges from 20 to 60 h, with a mean of about 40 h
(Ufer, 2005; Beinema et al, 2008).
Several other models included an INR ≥ 45 during a pre-
vious hospital admission in the final model (Beyth et al,
1998; Kuijer et al, 1999; Gage et al, 2006; Pisters et al, 2010;
Fang et al, 2011), but this was not confirmed in our study. A
reason for this may be that two subsequent hospitalizations
are totally different (i.e. type of ward, concomitant medica-
tion, reason for hospitalization) and too far apart, with the
result that both hospitalisations cannot be compared to each
other.
Fig 1. Validation plots for the prediction model of an international
normalised ratio ≥ 45. (A) the calibration-in-the-large (a|b) was
034 and the calibration slope (slope b) was 106 before correction;
(B) after correction for the calibration-in-the-large, the calibration-
in-the-large was 0 and the calibration slope was 106. The distribu-
tion of predicted risks is shown at the bottom of the graphs. Trian-
gles indicate the observed proportions by quintiles of predicted risks.
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Elevated liver enzymes (ALAT, ASAT, GGT and LDH)
may indicate inflammation or damage to cells in the liver.
The observed association in this study of an increased LDH
with an increased risk of an INR ≥ 45 could be the result of
a deteriorating capacity of the liver to produce clotting
factors or to metabolise VKAs properly. The same association
was expected between ALAT, ASAT, GGT and INR ≥ 45.
However, patients with an elevated ALAT level had a lower
risk of an INR ≥ 45 and ASAT and GGT showed no rela-
tionship with INR ≥ 45 in this study. As shown in Table II,
Fig 2. Screenshot of the spreadsheet with cal-
culations for an individual patient using the
prediction model. aAge (=0, for age ≤60 years;
=age (in years) – 60, for age >60 years). ALAT
alanine amino transferase; CRP: C-reactive
protein; e-GFR estimated glomerular filtration
rate, calculated with the modification of diet in
renal disease formula (Levey et al, 1999); INR,
international normalised ratio; LDH, lactate
dehydrogenase.
Table III. Prediction model.
Steps Formula
1. Calculate lp “all variables”a =0016 9 Ageb + 0176 9 Genderc0003 9 ALATd + 0580 9
log(LDH)e0042 9 Albuminf0009 9 e-GFRg + 0206 9 log(CRP)h
+ 0617 9 Miconazolei + 0789 9 Cotrimoxazolej + 0987
9 Fluconazolek + 2237 9 Voriconazolel + 0826 9
Amiodaronem + 0587 9 Anti-thyroid drugsn
2. Calculate the lp with
the intercept
=4282 + lp
3. Calculate the prediction
of an INR ≥ 45
=[1/(1 + exp (lp))] 9 100%
ALAT, alanine amino transferase; CRP, C-reactive protein; e-GFR, estimated glomerular filtration rate, calculated with the modification of diet in
renal disease formula (Levey et al, 1999); INR, international normalised ratio; LDH, lactate dehydrogenase.
alp refers to the linear predictor in a logistic regression model.
bAge (=0, for age ≤60 years; =age (in years) – 60, for age >60 years).
cGender (female = 1, male = 0).
dALAT (alanine amino transferase) in u/l.
eLDH (lactate dehydrogenase) in u/l.
fAlbumin in g/l.
ge-GFR (estimated glomerular filtration rate) in ml/min/173 m2.
hCRP (c-reactive protein) in mg/l.
iConcomitant use of miconazole (yes = 1, no = 0).
jConcomitant use of cotrimoxazole (yes = 1, no = 0).
kConcomitant use fluconazole (yes = 1, no = 0).
lConcomitant use of voriconazole (yes = 1, no = 0).
mConcomitant use of amiodarone (yes = 1, no = 0).
nConcomitant use of anti-thyroid drugs (yes = 1, no = 0).
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the observed ALAT and ASAT levels in our population were
not very high. This may be the reason that our findings are
contrary to what we expected.
Higher concentrations of albumin were predictive for a
decreased risk of an INR ≥ 45. VKAs bind to albumin in
plasma and only unbound drugs have a pharmacological
effect. Another possible explanation is that lower concentra-
tions of albumin represent a deteriorating condition of the
patient resulting in a reduced intake of vitamin K.
Patients with a high e-GFR have a 07-fold (95% CI, 06–
08) lower risk of an INR ≥ 45 than patients with a low
renal function. However, the VKA elimination does not
depend on renal function so a causal link cannot be estab-
lished. VKAs are mainly metabolised by liver enzymes to
inactive metabolites that are excreted in the urine. The posi-
tive effect of a good renal function may be the result of a
better condition of the patient in general.
Our results also showed that high CRP levels were predic-
tive for an increased risk of an INR ≥ 45. CRP has a positive
association with infections and inflammations, which might
affect coagulation. A potential mechanism for the higher risk
of an INR ≥ 45 during infections and inflammations is the
increased catabolism of vitamin K dependent clotting factors
and inhibition of VKA metabolism (Timothy et al, 2015).
Most models that have been developed by others use bin-
ary values for age groups, liver and renal disease (Kuijer
et al, 1999; Beyth et al, 2002; Gage et al, 2006; Pisters et al,
2010; Fang et al, 2011). Our final prediction model consists
of predictors with continuous values for age and for labora-
tory values. This makes it difficult to compare our model to
other models. The predictors, age (Beyth et al, 1998; Kuijer
et al, 1999; Gage et al, 2006; Ruiz-Gimenez et al, 2008; Pis-
ters et al, 2010; Fang et al, 2011) and renal function (Beyth
et al, 1998; Kuijer et al, 1999; Gage et al, 2006; Ruiz-Gime-
nez et al, 2008; Pisters et al, 2010; Fang et al, 2011) seem to
be present in most models. Our model includes several con-
comitant medications that are easily extractable from the
EMR.
Limitations
The first limitation is that we used a surrogate marker for an
increased risk of bleeding. We would have preferred to pre-
dict bleeding itself, but that complication was not registered
in an easily extractable way in the EMR. An INR ≥ 45 is an
adequatemarkerbecause 45 is the level atwhich the riskof bleed-
ing increases sharply (Palareti et al, 1996; Hylek et al, 2003;
Amouyel et al, 2009). Second, although we had many candidate
predictors, several potentially significant predictors were not
available. For example, information on the indication for VKA
treatment or on the target INR was lacking. Patients with a
mechanical heart valve, for example, have a higher target INR
(25–35) than patients with atrial fibrillation, where the target
INR ranges from 20 to 30 (Kirchhof et al, 2016). Patients with a
higher target INR are therefore more susceptible to reach a
supratherapeutic INR (Meschengieser et al, 1997). We couldn’t
include comorbidities, because they were not extractable from
the EMR. Furthermore, this study has included all adult patients
admitted to the hospital, except those admitted to the ICU. This
might introduce selection bias because patients who have been
transferred to the ICU represent a special group of patients with
increased disease severity that is not represented in this study.
Finally, the studywasperformed inoneuniversityhospital,which
may limitgeneralizability.
Strengths
Notwithstanding these limitations, the strong point of our
study is that we included all adult patients admitted to medi-
cal or surgical wards of the hospital. Another strength is that
we validated our model, which showed that the prediction
model is applicable to patients that were hospitalised in a
different time period than that of our development cohort.
Furthermore, the predictors in the model are extracted from
the EMR, which makes it possible to develop an electronic
prediction rule, enabling doctors to easily assess the individ-
ual risks of an INR ≥ 45.
Implications
This study shows that it is possible to develop an electronic
prediction rule for an INR ≥ 45 in hospitalised patients
using VKAs. The prediction model can help physicians to
identify patients at the lower spectrum of thromboembolic
risk and those for whom the risk of bleeding during VKA
therapy is high. Using the prediction model may also help
when counselling and informing patients about their poten-
tial risk for haemorrhage while on anticoagulants, and in
identifying those patients who might benefit from more care-
ful management of anticoagulation. Alternatively, these
patients can also be switched to direct oral anticoagulants
(DOACs), which cause less major bleeding, such as intracra-
nial haemorrhages, compared to VKAs (Adam et al, 2012).
The methodology for developing an electronic prediction
rule for VKAs used in our study may also be applied to other
anticoagulants, such as the DOACs. Future studies are neces-
sary to further improve the prediction model by including
patients admitted to the ICU, and by incorporating time in
the therapeutic range (TTR) which is associated with the
effectiveness and safety of VKA therapy (Lin et al, 2017).
Furthermore, information about the indication of the
VKA, the duration of use of VKAs before admission and
comorbidities can be included to the prediction model to
investigate whether it leads to a more accurate prediction
model. Ideally, a prospective intervention study should be
performed after implementation of the electronic prediction
rule, to investigate whether the use of such a rule leads to a
decrease in the number of admissions during which an
INR ≥ 45 occurs and whether this results in less bleeding
complications.
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Conclusions
We developed a clinical prediction rule with a c-statistic of
071 for an INR ≥ 45 in patients admitted to medical or
surgical wards who are treated with VKAs. The model
includes several risk factors, including concomitant medica-
tion, which are easily extractable from electronic patient
records. This enables the creation of a clinical decision sup-
port rule, based on the prediction model identified in this
study.
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